Questions Surface In Response To FDA's Draft Guidance On Device Animal Studies
This article was originally published in The Gray Sheet
Executive Summary
Industry and regulatory groups say FDA should make it clearer in a final guidance whether it intends to only address animal studies assessing safety or if it is also targeting performance studies in a draft guidance from October. There are also questions about reporting of raw data from animal studies, and PETA weighs in.
You may also be interested in...
J&J Pledges To Stop Animal Use In Sales Training
The manufacturer was facing PETA protests in response to a leaked plan to allow pigs to die as part of sales-rep training later this month.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.